ArticleJournal of medical virology2026
Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This study aimed to assess the humoral immune response following administration of a BNT162b2 mRNA COVID-19 booster dose and to evaluate its association with the development of SARS-CoV-2 infection after vaccination. Between July 2021 and February 2022, serum samples were collected from 313 individuals 28 days after receiving a COVID-19 booster dose. Quantitative SARS-CoV-2 IgG antibodies directed against the receptor-binding domain (RBD) of the spike protein were measured using a chemiluminescent microparticle immunoassay. Neutralizing antibody activity, defined as inhibition of the RBD-ACE2 interaction, was evaluated semi-quantitatively by a competitive ELISA. Participants were followed for 6 months after the final dose to identify confirmed SARS-CoV-2 infections. The cohort included 97 males (31%) and 216 females (69%), with a mean age of 39.43 years. The median SARS-CoV-2 IgG antibody level at day 28 was 7713.3 AU/mL, and the median neutralizing antibody inhibition rate was 99.2%. Antibody levels were not significantly associated with age or comorbidities. Booster vaccination induced a strong humoral immune response in all participants. However, the occurrence of post-vaccination infections despite high antibody levels suggests immune escape by emerging variants. While vaccines may not fully prevent infection, they provide substantial protection against severe disease and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.